Erik A Williams,Isabella Vegas,Fardous F El-Senduny,Jessica Zhang,Douglas A Mata,Matthew C Hiemenz,Sarah R Hughes,Brianna C Sa,Garrett P Kraft,Nicole Gorbatov,Kathleen Foley-Peres,Edward Z Sanchez,Clara Milikowski,Kevin Jon Williams,Jeffrey S Ross,Razelle Kurzrock,Elizabeth A Montgomery,David B Lombard,Surinder Kumar,Erik A. Williams,Fardous F. El-Senduny,Douglas A. Mata,Matthew C. Hiemenz,Sarah R. Hughes,Brianna C. Sa,Garrett P. Kraft,Edward Z. Sanchez,Jeffrey S. Ross,Elizabeth A. Montgomery,David B. Lombard

Abstract:Myxofibrosarcoma (MFS) is a common soft tissue sarcoma of the elderly that typically shows low tumor mutational burden, with mutations in TP53 and in genes associated with cell cycle checkpoints ( RB1 , CDKN2A ). Unfortunately, no alterations or markers specific to MFS have been identified and, as a consequence, there are no effective targeted therapies. The receptor tyrosine kinase AXL, which drives cellular proliferation, is targetable by new antibody-based therapeutics. Expression of AXL messenger RNA is elevated in a variety of sarcoma types, with the highest levels reported in MFS, but the pathogenic significance of this finding remains unknown. To assess a role for AXL abnormalities in MFS, we undertook a search for AXL genomic alterations in a comprehensive genomic profiling database of 463,546 unique tumors (including 19,879 sarcomas, of which 315 were MFS) interrogated by targeted next-generation DNA and/or RNA sequencing. Notably, the only genomic alterations recurrent in a specific sarcoma subtype were AXL W451C (n = 8) and AXL W450C (n = 2) mutations. The tumors involved predominantly older adults (age: 44 to 81 [median: 72] y) and histologically showed epithelioid and spindle-shaped cells in a variably myxoid stroma, with 6 cases diagnosed as MFS, 3 as undifferentiated pleomorphic sarcoma (UPS), and 1 as low-grade sarcoma. The AXL W451C mutation was not identified in any non-sarcoma malignancy. A review of publicly available data sets revealed a single AXL W451C-mutant case of UPS that clustered with MFS/UPS by methylation profiling. Functional studies revealed a novel activation mechanism: the W451C mutation causes abnormal unregulated dimerization of the AXL receptor tyrosine kinase through disulfide bond formation between pairs of mutant proteins expressing ectopic cysteine residues. This dimerization triggers AXL autophosphorylation and activation of downstream ERK signaling. We further report sarcomas of diverse histologic subtypes with AXL gene amplifications, with the highest frequency of amplification identified in MFS cases without the W451C mutation. In summary, the activating AXL W451C mutation appears highly specific to MFS, with a novel mechanism to drive unregulated signaling. Moreover, AXL gene amplifications and messenger RNA overexpression are far more frequent in MFS than in other sarcoma subtypes. We conclude that these aberrations in AXL are distinct features of MFS and may aid diagnosis, as well as the selection of available targeted therapies.

Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma

Advancements in the understanding and management of histiocytic neoplasms

High Frequency of Clonal Immunoglobulin Receptor Gene Rearrangements in Sporadic Histiocytic/Dendritic Cell Sarcomas

A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations

Case Report: Long-Term Response to Radiotherapy Combined With Targeted Therapy in Histiocytic Sarcoma Harboring Mutations in MAPK and PI3K/AKT Pathways

Malignant Progression of an Ancestral Bone Marrow Clone Harboring Acic-Nutm2afusion in Isolated Myeloid Sarcoma

Potential Application of Genomic Profiling for the Diagnosis and Treatment of Patients with Sarcoma.

Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy

Genomic And Molecular Characterization Of Malignant Peripheral Nerve Sheath Tumor Identifies The Igf1r Pathway As A Primary Target For Treatment (Publication With Expression Of Concern. See Vol. 25, Pg. 3195, 2019)

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium

Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma

Mutually Exclusive Recurrent Somatic Mutations in MAP2K1 and BRAF Support a Central Role for ERK Activation in LCH Pathogenesis

Comprehensive Genomic Profiling of Sarcomas in Chinese Population.

Identification of Therapeutic Targets in Rhabdomyosarcoma Through Integrated Genomic, Epigenomic, and Proteomic Analyses.

Canine Histiocytic and Hemophagocytic Histiocytic Sarcomas Display KRAS and Extensive PTPN11/SHP2 Mutations and Respond In Vitro to MEK Inhibition by Cobimetinib

Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell Histiocytosis.

Diagnostic and Therapeutic Implications of a FUS::TFCP2 Fusion and ALK Activation in a Metastatic Rhabdomyosarcoma

A Novel Fusion Gene PLEKHA6-NTRK3 in Langerhans Cell Histiocytosis

Synchronous Pulmonary Langerhans Cell Histiocytosis and Multiple Cutaneous Reticulohistiocytomas With a Common BRAF-V600E/D Mutation Driver

Genetic Screen in a Pre-Clinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities

Phosphoproteomics Identifies Driver Tyrosine Kinases In Sarcoma Cell Lines And Tumors